First author [Ref.] | Treatment n/N | Control n/N | Weight % | RR (95% CI)# |
Atypical versus no atypical coverage¶ | ||||
Kinasewitz 16 | 30/32 | 39/39 | 18.66 | 0.94 (0.86–1.03) |
MacFarlane 17 | 174/214 | 191/212 | 21.13 | 0.90 (0.83–0.98) |
Donowitz 11 | 122/168 | 115/162 | 11.37 | 1.02 (0.89–1.17) |
O’Doherty 14 | 87/114 | 85/111 | 10.30 | 1.00 (0.86–1.15) |
Salvarezza 15 | 30/30 | 29/30 | 24.02 | 1.03 (0.97–1.11) |
Petitpretz 13 | 39/41 | 37/40 | 14.52 | 1.03 (0.92–1.15) |
Overall | 482/599 | 496/594 | 100 | 0.98 (0.93–1.04) |
Macrolide versus fluoroquinolone¶ | ||||
Fogarty 18 | 178/188 | 184/194 | 34.82 | 1.00 (0.95–1.05) |
Ramirez 19 | 145/175 | 133/167 | 8.40 | 1.04 (0.94–1.15) |
Hoeffken 12 | 164/174 | 336/357 | 37.80 | 1.00 (0.96–1.05) |
Gotfried 9 | 113/128 | 107/124 | 9.78 | 1.02 (0.93–1.12) |
Sokol 20 | 74/85 | 63/66 | 9.20 | 0.91 (0.83–1.01) |
Overall | 674/750 | 823/908 | 100 | 1.00 (0.97–1.03) |
Cephalosporins versus β-lactams/β-lactamase inhibitors¶ | ||||
Higuera 21 | 55/55 | 49/51 | 50.33 | 1.04 (0.97–1.11) |
Fogarty 10 | 268/301 | 130/144 | 49.67 | 0.99 (0.92–1.05) |
Overall | 323/356 | 179/195 | 100 | 1.01 (0.95–1.08) |
RR: risk ratio; CI: confidence interval. #: the RR was calculated using a random effects model; ¶: treatment versus control.